OxOnc to Partner with Pfizer on China Cancer Drug Trial
publication date: Feb 11, 2013
OxOnc Development LLP, an oncology company headquartered in Princeton, NJ, has signed a co-development agreement with Pfizer to conduct a Phase III clinical trial of a Pfizer cancer drug in China, Taiwan, Japan and South Korea. The drug, crizotinib (marketed as Xalkori®), will be tested in patients with advanced non-small cell lung cancer who have a ROS1 (c-ros) gene rearrangement (ROS1-positive). The drug is already approved in the US, Europe, China and Japan for NSCLC patients with the ALK genetic variation. More details....
Stock Symbol: (NYSE: PFE)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.